EyeGate Adds $6M to Series D

Xconomy Boston — 

Waltham, MA-based EyeGate Pharmaceuticals announced yesterday that it added $5.9 million to its Series D funding round, bringing the financing’s total to $28.5 million to date. The biotech works on delivering drugs to the eye, and said the new money will go toward EGP-437, its dexamethasone-derived corticosteroid treatment for dry eye syndrome. In September Eyegate inked a partnership deal with Worcester, MA-based RXi Pharmaceuticals (NASDAQ: RXII) to deliver RNA interference therapeutics to the eye for the treatment of retinal disorders.